BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29667815)

  • 1. Theranostic Pt(IV) Conjugate with Target Selectivity for Androgen Receptor.
    Qin X; Fang L; Zhao J; Gou S
    Inorg Chem; 2018 May; 57(9):5019-5029. PubMed ID: 29667815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-generation testosterone-platinum(II) hybrids for site-specific treatment of androgen receptor positive prostate cancer: Design, synthesis and antiproliferative activity.
    Ouellette V; Côté MF; Gaudreault RC; Tajmir-Riahi HA; Bérubé G
    Eur J Med Chem; 2019 Oct; 179():660-666. PubMed ID: 31279298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coordination-driven self-assembly of a Pt(iv) prodrug-conjugated supramolecular hexagon.
    Yue Z; Wang H; Li Y; Qin Y; Xu L; Bowers DJ; Gangoda M; Li X; Yang HB; Zheng YR
    Chem Commun (Camb); 2018 Jan; 54(7):731-734. PubMed ID: 29303526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
    Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
    Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
    Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cancer specific oxaliplatin-releasing Pt(iv)-prodrug.
    Reshetnikov V; Arkhypov A; Julakanti PR; Mokhir A
    Dalton Trans; 2018 May; 47(19):6679-6682. PubMed ID: 29708261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tailoring Platinum(IV) Amphiphiles for Self-Targeting All-in-One Assemblies as Precise Multimodal Theranostic Nanomedicine.
    He S; Li C; Zhang Q; Ding J; Liang XJ; Chen X; Xiao H; Chen X; Zhou D; Huang Y
    ACS Nano; 2018 Jul; 12(7):7272-7281. PubMed ID: 29906087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent Pt
    Ma L; Wang N; Ma R; Li C; Xu Z; Tse MK; Zhu G
    Angew Chem Int Ed Engl; 2018 Jul; 57(29):9098-9102. PubMed ID: 29806087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.
    Xu Z; Hu W; Wang Z; Gou S
    Eur J Med Chem; 2017 Dec; 141():211-220. PubMed ID: 29031068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel hypoxia-targeting Pt(iv) prodrugs.
    Xu Z; Zhao J; Gou S; Xu G
    Chem Commun (Camb); 2017 Mar; 53(26):3749-3752. PubMed ID: 28303266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
    Xiao H; Yan L; Zhang Y; Qi R; Li W; Wang R; Liu S; Huang Y; Li Y; Jing X
    Chem Commun (Camb); 2012 Nov; 48(87):10730-2. PubMed ID: 23012698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
    Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
    Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.
    Saito Y; Mizokami A; Tsurimoto H; Izumi K; Goto M; Nakagawa-Goto K
    Eur J Med Chem; 2018 Sep; 157():1143-1152. PubMed ID: 30189396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs?
    Schmidt C; Babu T; Kostrhunova H; Timm A; Basu U; Ott I; Gandin V; Brabec V; Gibson D
    J Med Chem; 2021 Aug; 64(15):11364-11378. PubMed ID: 34342437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer.
    Kandil S; Westwell AD; McGuigan C
    Bioorg Med Chem Lett; 2016 Apr; 26(8):2000-4. PubMed ID: 26965862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment.
    Liang JJ; Xie H; Yang RH; Wang N; Zheng ZJ; Zhou C; Wang YL; Wang ZJ; Liu HM; Shan LH; Ke Y
    Bioorg Med Chem; 2021 Sep; 45():116331. PubMed ID: 34364224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
    Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
    Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative mechanism of action of the DNP Pt
    Krasnovskaya O; Spector D; Erofeev A; Gorelkin P; Akasov R; Skvortsov D; Trigub A; Vlasova K; Semkina A; Zyk N; Beloglazkina E; Majouga A
    Dalton Trans; 2021 Jun; 50(23):7922-7927. PubMed ID: 34037020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cis,cis,trans-[Pt
    Ravera M; Gabano E; Zanellato I; Rangone B; Perin E; Ferrari B; Bottone MG; Osella D
    Dalton Trans; 2021 Mar; 50(9):3161-3177. PubMed ID: 33595015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitric oxide-releasing platinum(IV) prodrug efficiently inhibits proliferation and metastasis of cancer cells.
    Dai Y; Zhu Y; Cheng J; Shen J; Huang H; Liu M; Chen Z; Liu Y
    Chem Commun (Camb); 2020 Nov; 56(90):14051-14054. PubMed ID: 33103676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.